RedChip

The World Leader in Small-Cap Investor Relations.
Read our Disclosures:

[RedChip @RedChip]

ASP Isotopes $ASPI: CEO Paul Mann Outlines a Scalable Critical Materials Growth Story

@ASPIsotopes is targeting some of the most important supply chains in the world, including nuclear medicine, nuclear fuel, semiconductors, and advanced materials.

What stands out:
• Three plants built in South Africa over three years
• Commercial ramp expected in 2026
• U.S. expansion strategy aimed at securing supply of critical materials historically sourced from Russia
• Exposure to multiple high-value end markets with growing geopolitical relevance

Watch our full $ASPI investor overview: https://t.co/DEu5KQtCJE

$ASPI $SMR $NNE $OKLO $UUUU $CEG $VST $CCJ $UEC $LEU $GEV $BEP

[RedChip @RedChip]

LanzaTech Global (Nasdaq: $LNZA): Carbon Recycling at Commercial Scale — From Waste to Fuel

LanzaTech's mission is straightforward but profound: create a post-pollution future where waste carbon is the building block from which everything is made,

Why Clean Energy Investors Are Watching:
• Proven technology: Commercial plants already operating across Asia and Europe
• SAF is under structural demand pressure as aviation decarbonization mandates accelerate globally
• Capital-light model: LanzaTech licenses its technology and biocatalysts, reducing capital intensity
• Feedstock flexibility: The platform converts CO, CO₂, and hydrogen from steel mills, landfill gas, agricultural waste, and other industrial sources

CEO Dr. Jennifer Holmgren presents at 12:30 PM ET on June 10.

Register free: https://t.co/F6isjDz8Ci

$LNZA $GEVO $CLMT $WM

[RedChip @RedChip]

Nexalin Technology (Nasdaq: $NXL): New U.S. Patent Extends Protection for Core DIFS™ Technology Through 2042

Nexalin has received a U.S. patent covering its dynamic frequency stimulation methods for anxiety, depression, and insomnia, further strengthening Nexalin's position as it advances its non-invasive neurostimulation technology across clinical, regulatory, and commercial development initiatives.

Why Investors Should Be Watching:
• Long-term protection for Nexalin's core neurostimulation technology
• Patent coverage spans three of the company's primary mental health targets
• FDA-focused insomnia program remains a key clinical catalyst
• Growing IP portfolio reinforces competitive position in frequency-based neurostimulation

For the full announcement: https://t.co/r3TaNFeHfe

$NXL $VRTX $STIM $NMTC $LLY $AMGN $REGN $GILD $MRNA

[RedChip @RedChip]

Greenwich LifeSciences, Inc. (Nasdaq: $GLSI): CEO Snehal Patel Discusses GP2 Immunotherapy and Phase III Strategy

In our most recent interview, CEO Snehal Patel outlines the company’s clinical and strategic roadmap for GP2, an immunotherapy designed to prevent breast cancer recurrences in HER2-positive patients following surgery.

Key Takeaways for Investors:
• Robust Phase IIb Data: GP2 achieved over 80% reduction in recurrence rates over five years, significantly outperforming existing therapies in the adjuvant setting.
• Strong Safety Profile: No serious adverse events reported across 146 patients in four clinical trials.
• Global Phase III Trial: FLAMINGO-01 is enrolling up to 750 patients across 150 clinical sites in the US and Europe in partnership with leading oncology networks.

Hear directly from leadership about how Greenwich LifeSciences is positioning GP2 for commercial success and long-term impact.

https://t.co/JQi7TsgVTf

$GLSI $PFE $LLY $JNJ $NVS $AZN $PBYI $BNTX $MRK $HOLX $IMCR

[RedChip @RedChip]

Anixa Biosciences $ANIX: Breast Cancer Vaccine Program Advances Following Phase 1 Clinical Milestone

Breast cancer represents a $38B+ market opportunity, projected to reach nearly $90B by 2030. Anixa Biosciences is advancing a first-in-class breast cancer vaccine program developed with Cleveland Clinic and funded by the U.S. Department of War.

$ANIX is targeting one of oncology’s largest markets with a capital-efficient biotech model and a vaccine platform designed to both treat and potentially prevent breast cancer.

Watch our 30-second investor brief: https://t.co/odFMB9dJ53

$ANIX $PFE $LLY $JNJ $NVS $AZN $PBYI $BNTX $MRK $HOLX $IMCR

[RedChip @RedChip]

Off The Hook Yachts $OTH is expanding from an already proven growth foundation.

In our investor overview, CEO Brian John breaks down what is driving the story:
• Market leadership in used boat sales
• AI-driven platform built to reduce mistakes and improve inventory turns
• Floor plan expansion from $25M to $60M, unlocking significantly more buying power
• Apex Marine Group acquisition adding revenue potential, Florida locations, and cost-saving synergies

For investors looking for a small-cap growth story with acquisitions, operational leverage, and a scalable platform, $OTH's overview is worth watching.

Watch here: https://t.co/0teF2obI4e

$OTH $BC $HZO $MBUU $ONEW $MCFT $MPX $WGO

[RedChip @RedChip]

Foremost Clean Energy $FMST: Athabasca Basin Uranium Explorer Positioned Against a Shifting Nuclear Policy Backdrop

Foremost Clean Energy is actively drilling in the Athabasca Basin, the world's highest-grade uranium jurisdiction, across a 330,000+ acre portfolio backed by the technical expertise of their partners.

Why investors are watching:
- U.S. policy now targets 4x current nuclear capacity
- Strategic partnership with Denison Mines provides historical drilling data and geological expertise across all 10 properties
- $9M 2026 exploration budget with active drill programs underway
- Nasdaq-listed, tight float of 10.6M shares, zero long-term debt

Learn more: https://t.co/G3vOREit7U

$FMST $DNN $CCJ $UEC $NXE $UUUU $RIO $SQM $ALB

[RedChip @RedChip]

New Horizon Aircraft (Nasdaq: $HOVR): 38-Year Aerospace Engineering Veteran Joins to Support Cavorite X7 Certification

New Horizon Aircraft has appointed Richard Alexander as Chief Engineer of Certified Programs, adding a veteran aerospace engineer as the company advances certification and commercialization of its hybrid-electric Cavorite X7 VTOL aircraft.

Alexander brings 38 years of aircraft development experience spanning commercial aviation, eVTOL, and electric aircraft programs. His background includes engineering leadership roles at Bombardier, Head of Flight Physics for Vertical Aerospace's VX4 eVTOL program, and most recently leading CAE's Electric Aircraft Integrator function for the battery-electric conversion of the Piper Archer training aircraft.

Why Investors Should Be Watching:
• Certification expertise: Alexander's background aligns directly with Horizon's next phase as it advances the Cavorite X7 through certification
• eVTOL experience: His work on Vertical Aerospace's VX4 program provides firsthand experience with the technical and regulatory demands of advanced air mobility aircraft

For the full press release: https://t.co/r9j04H6uZX

$XTIA $UMAC $RCAT $NOC $LHX $BA $AVAV $KTOS $ONDS $PLTR $NVDA

[RedChip @RedChip]

Exyn Technologies (Nasdaq: $EXYN): COO Presents ExynAI at UN-Hosted Drone Forum Focused on Security, Resilience, and Mission-Critical Applications

Exyn Technologies' Chief Operating Officer Ben Williams presented yesterday at ROTH Capital Partners' Drone Technology in Global Development event, held at the United Nations in New York City. The forum brought together diplomatic representatives, investors, and public and private drone companies to discuss the role of autonomous systems in security, resilience, and mission-critical operations.

Exyn's presentation highlighted ExynAI, the company's proprietary Level 4B autonomy engine that enables aerial and ground robotic systems to navigate, map, and collect real-time 3D data in GPS-denied, communications-denied, and previously unmapped environments.

For the full press release: https://t.co/qjDxa5vCii

$ONDS $RCAT $AVAV $TRMB $TDY $KTOS $OUST $UMAC $DPRO $MVIS

[RedChip @RedChip]

BioVie (Nasdaq: BIVI): 2 Clinical Assets, Multiple Catalysts, Multi-Billion-Dollar Market Targets

BioVie is advancing a differentiated pipeline focused on neurodegenerative disease and liver disease, with CEO Cuong Do outlining why investors are watching the next phase of the company’s development.

BioVie is operating at the intersection of large patient populations, high unmet need, and potential multi-billion-dollar commercial opportunities, including estimated U.S. market opportunities of $30B in Alzheimer’s, $3B in Parkinson’s, and $1.6B in ascites.

For investors tracking clinical-stage biotech catalysts, BIVI is well worth a closer look.
Watch the full CEO-guided overview: https://t.co/FU3A4QDh6i

$BIVI $SXTP $INAB $DMAC $BFRG $NSRX $CLDI $NXL $CNTB $LTRN $KYNB $ANIX

[RedChip @RedChip]

⚛️ Rare earth elements are essential inputs for advanced industrial systems, including power generation, communications infrastructure, defense technologies, and high-performance manufacturing.

Avalon Advanced Materials Inc. (TSX: AVL | OTCQB: AVLNF) is advancing the Nechalacho Rare Earth Project, one of the most strategically significant rare earth assets in North America, with both light and heavy rare earth content.

🔗 Learn more about Avalon’s rare earth strategy: https://t.co/0nqnTJc0Ng

S&P Global Energy Breaking Defense TechCrunch #AVL #AVLNF #InvestorWebinar #CriticalMinerals #SmallCapStocks #EVMaterials

[RedChip @RedChip]

Greenwich LifeSciences $GLSI: CEO Snehal Patel Discusses GP2 Immunotherapy and Phase III Strategy

In our most recent interview, CEO Snehal Patel outlines the company’s clinical and strategic roadmap for GP2, an immunotherapy designed to prevent breast cancer recurrences in HER2-positive patients following surgery.

Key Takeaways for Investors:
• Robust Phase IIb Data: GP2 achieved over 80% reduction in recurrence rates over five years, significantly outperforming existing therapies in the adjuvant setting.
• Strong Safety Profile: No serious adverse events reported across 146 patients in four clinical trials.
• Global Phase III Trial: FLAMINGO-01 is enrolling up to 750 patients across 150 clinical sites in the US and Europe in partnership with leading oncology networks.

Hear directly from leadership about how @GreenwichLS is positioning GP2 for commercial success and long-term impact.

Watch the whole interview: https://t.co/6bROX41nnt

$GLSI $PFE $LLY $JNJ $NVS $AZN $MRK $HOLX $IMCR

[RedChip @RedChip]

NioCorp Developments $NB: CEO Mark Smith on 2025 Progress and the Advancing Path to Construction at Elk Creek

$NB CEO Mark A. Smith reviews a pivotal year for NioCorp Developments — covering $370.8M raised in 2025, the launch of the $45M Mine Portal Project, advancing U.S. Export-Import Bank financing, and a Pentagon-funded partnership with Lockheed Martin and Skunk Works on scandium defense technology.

Watch the full CEO interview: https://t.co/A1gWL26cD8

$NB $MP $ARA $ILU $PPTA $TECK $KGC $USGO $NG $THM $WRN $HL $GPH $NST $FVL $CTGO

[RedChip @RedChip]

Calidi Biotherapeutics $CLDI: RedTail Systemic Virotherapy Platform Advances Toward IND Submission as CEO Eric Poma Outlines the Investment Case

$CLDI CEO Eric Poma, PhD explains how Calidi's proprietary RedTail platform addresses one of oncology's most persistent challenges: delivering oncolytic virotherapy systemically to metastatic tumors without immune clearance eliminating the therapy before it reaches its target.

Watch the full interview: https://t.co/XILoqV1Bcg

$CLDI $PFE $AMGN $JNJ $CADL $BMRN $CPRX $CGON $REPL $NBTX $IBRX

[RedChip @RedChip]

Watch Now: Comprehensive Healthcare Systems $CMHSF CEO Interview on Healthcare SaaS and Pipeline Growth

In our exclusive interview, CEO Chris Cosgrove breaks down the company’s strategy to scale in the healthcare benefits administration market, a multibillion-dollar opportunity.

For investors looking at underfollowed healthcare SaaS names, our interview lays out the compelling growth strategy, margin profile, and market opportunity.

Watch our full interview: https://t.co/dZ5RVqmrR7

$CMHSF $CHS $VEEV $GEHC $PME $TDOC $DOCS $HIMS $CERT $DH $TEM $ALKT

[RedChip @RedChip]

BioVie $BIVI: 2 Clinical Assets, Multiple Catalysts, Multi-Billion-Dollar Market Targets

@BioVie_Pharma is advancing a differentiated pipeline focused on neurodegenerative disease and liver disease, with CEO Cuong Do outlining why investors are watching the next phase of the company’s development.

$BIVI operates at the intersection of large patient populations, high unmet need, and potential multi-billion-dollar commercial opportunities, including estimated U.S. market opportunities of $30B in Alzheimer’s, $3B in Parkinson’s, and $1.6B in ascites.

For investors tracking clinical-stage biotech catalysts, $BIVI is well worth a closer look.

Watch the full CEO-guided overview: https://t.co/84cxybEC6G

$BIVI $PACB $VYGR $PFE $MRK

[RedChip @RedChip]

Exclusive Interview: $BESS Co-CEO Bob Brilon Breaks Down Bimergen’s $250M Backing, 2GW BESS Pipeline, and Scalable Growth Strategy

Utility-scale battery storage is one of the fastest-growing segments in energy, and @BimergenEnergy is stepping up with a 2GW pipeline, $250M equity commitment, and contract-backed revenue model.

Watch our full interview now: https://t.co/LzAG5VG9PR

$BESS $NEE $FLNC $STEM $BE $ENPH $TSLA $GNRC $EOSE

[RedChip @RedChip]

Money still moves slower than data.

Stablecoins change that—and OBOOK Holdings (OwlTing Group; Nasdaq: $OWLS) is building the rails to make it work inside the financial system.

Hear directly from the CEO on why @OwlTing Group is positioning itself as the backbone of next-gen global payments.

Full article + interview: https://t.co/Kb7nQsTh3b

$OWLS $COIN $PYPL $SQ $NATL $MARA $RIOT $MSTR $NVDA

[RedChip @RedChip]

Alliance Entertainment: Executive Chairman Bruce Ogilvie on Strategy & Execution

$AENT's growth priorities: scaling higher-margin exclusive content, expanding direct-to-consumer fulfillment, and leveraging automation to enhance profitability.

Why Investors Should Watch:
• Insight into how $AENT aligns operational execution with long-term shareholder value, targeting durable growth across premium entertainment and collectibles segments.

Learn more: https://t.co/JlMGBOkoDc

$AENT $FNKO $SONY $DIS $PARA $WBD $NTDOY

[RedChip @RedChip]

For investors ​evaluating deep-sea ​mining, permitting visibility is ​critical.

Recent ​legal ​analysis ​highlights how the U.S. ​Deep ​Seabed ​Hard Mineral Resources Act ​(DSHMRA) provides ​a ​long-established, ​transparent ​permitting framework for ​U.S. nationals operating ​in international waters.

This legitimate ​legal foundation--reaffirmed and ​advanced ​over multiple ​decades ​and administrations ​of both parties--underpins ​the ​regulatory certainty enabling companies such as @themetalsco $TMC ​to prepare ​for world-first ​commercial operations, ​currently expected in Q4 ​2027.

Learn more: https://t.co/nKbk6rWP6S